EP 161: How large language models can help build immunotherapies with Michelle Teng of Etcembly Ltd.

2024/11/14

The Genetics Podcast

Frequently requested episodes will be transcribed first

Chapters

Shownotes Transcript

No transcript made for this episode yet, you may request it for free.

EP 161: How large language models can help build immunotherapies with Michelle Teng of Etcembly Ltd.

The Genetics Podcast

Intro to The Genetics Podcast

Welcome to Michelle

What is immunotherapy and how has it evolved?

Why do immunotherapy responses vary among individuals?

The next generation of T-cell receptor therapies

The Long Term Survivor Study: Purpose and Insights

Etcembly's approach to T-cell and antibody characterization

Leveraging machine learning for immune system understanding

The role of HLA in T-cell receptor biology

T-cell repertoires in long-term survivors

Training LLMs for immune system biology

Michelle’s journey from Immunocore to Etcembly

Starting a company during the pandemic and the rise of LLMs

Challenges in pre-clinical immunotherapy development

Michelle’s daughter’s rare genetic disease and the founding of SynaptixBio

The value of biobanks and registries in rare disease research

The role of patient parent groups in rare disease treatments

Closing remarks

Shownotes Transcript

EP 161: How large language models can help build immunotherapies with Michelle Teng of Etcembly Ltd. 50:35 Share

The Genetics Podcast

Intro to The Genetics Podcast

Welcome to Michelle

What is immunotherapy and how has it evolved?

Why do immunotherapy responses vary among individuals?

The next generation of T-cell receptor therapies

The Long Term Survivor Study: Purpose and Insights

Etcembly's approach to T-cell and antibody characterization

Leveraging machine learning for immune system understanding

The role of HLA in T-cell receptor biology

T-cell repertoires in long-term survivors

Training LLMs for immune system biology

Michelle’s journey from Immunocore to Etcembly

Starting a company during the pandemic and the rise of LLMs

Challenges in pre-clinical immunotherapy development

Michelle’s daughter’s rare genetic disease and the founding of SynaptixBio

The value of biobanks and registries in rare disease research

The role of patient parent groups in rare disease treatments

Closing remarks

Shownotes Transcript

EP 161: How large language models can help build immunotherapies with Michelle Teng of Etcembly Ltd.